You are here

  • Home
  • Archive
  • Volume 3, Issue 2
  • Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Article metrics

Article menu

Download PDFPDF

Psoriatic arthritis
Original article
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

 

Online download statistics by month:

Online download statistics by month: December 2017 to March 2024

AbstractFullPdf
Dec 2017686824
Jan 2018329334213
Feb 201817516991
Mar 201814013342
Apr 2018969737
May 201810610953
Jun 2018878843
Jul 2018686833
Aug 2018646418
Sep 2018727228
Oct 2018595928
Nov 2018616123
Dec 2018616116
Jan 2019464515
Feb 2019575625
Mar 2019878120
Apr 2019474622
May 2019575518
Jun 2019625923
Jul 2019444324
Aug 2019303023
Sep 2019414124
Oct 2019464621
Nov 2019282813
Dec 201921213
Jan 2020272715
Feb 2020242410
Mar 202017177
Apr 202014145
May 202026268
Jun 202020198
Jul 202024196
Aug 202023176
Sep 202029256
Oct 2020282710
Nov 2020231910
Dec 202018136
Jan 2021352412
Feb 2021161011
Mar 2021312415
Apr 202119167
May 2021121012
Jun 202115118
Jul 2021222010
Aug 2021494720
Sep 2021312712
Oct 2021282321
Nov 2021201917
Dec 202122163
Jan 2022202011
Feb 202221208
Mar 202227268
Apr 202226199
May 2022474313
Jun 202233313
Jul 202217145
Aug 202244398
Sep 202226256
Oct 2022323011
Nov 202225207
Dec 2022282811
Jan 202373739
Feb 202333323
Mar 202324227
Apr 202312123
May 2023161114
Jun 202310108
Jul 2023232211
Aug 202333314
Sep 202323209
Oct 202331287
Nov 202338379
Dec 202337375
Jan 202433328
Feb 2024252312
Mar 20245753111
Total333931861445